{"id":351027,"date":"2025-08-25T20:20:55","date_gmt":"2025-08-25T20:20:55","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-celldex-therapeutics\/"},"modified":"2025-08-25T20:20:55","modified_gmt":"2025-08-25T20:20:55","slug":"how-to-buy-celldex-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/","title":{"rendered":"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-351027","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - CLDX Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - CLDX Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Celldex Therapeutics (CLDX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Celldex Therapeutics (CLDX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin."},"intro":"\u0130leri biyoteknoloji yeniliklerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Celldex Therapeutics, imm\u00fcnoloji tedavilerinin heyecan verici s\u0131n\u0131r\u0131n\u0131 temsil ediyor. Devrim niteli\u011findeki barzolvolimab terapisi kronik inflamatuar durumlar i\u00e7in umut vaat ediyor; bu \u015firket, t\u0131bb\u0131n gelece\u011fine ve potansiyel olarak \u00f6nemli getiriler elde etmenize a\u00e7\u0131lan kap\u0131n\u0131z olabilir.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri biyoteknoloji yeniliklerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Celldex Therapeutics, imm\u00fcnoloji tedavilerinin heyecan verici s\u0131n\u0131r\u0131n\u0131 temsil ediyor. Devrim niteli\u011findeki barzolvolimab terapisi kronik inflamatuar durumlar i\u00e7in umut vaat ediyor; bu \u015firket, t\u0131bb\u0131n gelece\u011fine ve potansiyel olarak \u00f6nemli getiriler elde etmenize a\u00e7\u0131lan kap\u0131n\u0131z olabilir."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Celldex Therapeutics (CLDX) hisseleri <strong>22,46 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, son alt\u0131 ay i\u00e7indeki dramatik seyri g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda ilgin\u00e7 bir giri\u015f noktas\u0131 sunuyor.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: Takviminize <strong>5 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin! Celldex, bu tarihte bir sonraki kazan\u00e7 raporunu yay\u0131nlayacak. Tarihsel veriler, bu t\u00fcr olaylar\u0131n \u00f6nemli fiyat hareketlerine yol a\u00e7abilece\u011fini g\u00f6steriyor.<\/p> <h3>Kazan\u00e7 Etkisi Analizi: Tarih Bizlere Ne \u00d6\u011fretiyor<\/h3> <p>Son kazan\u00e7 tepkilerine bakmak, yat\u0131r\u0131m zamanlamas\u0131 i\u00e7in de\u011ferli dersler sunar:<\/p> <ul> <li><strong>7 A\u011fustos 2025 2. \u00c7eyrek Kazan\u00e7lar\u0131<\/strong>: Gelir tahminlerin alt\u0131nda kal\u0131rken, hisse ba\u015f\u0131na kazan\u00e7 (EPS) beklentileri hafif\u00e7e a\u015ft\u0131. Hisse senedi, kar\u0131\u015f\u0131k sonu\u00e7lara ra\u011fmen dayan\u0131kl\u0131l\u0131k g\u00f6sterdi ve uzun vadeli \u00fcr\u00fcn hatt\u0131na olan yat\u0131r\u0131mc\u0131 g\u00fcvenini yans\u0131tt\u0131 (<a href=\"https:\/\/www.stocktitan.net\/news\/CLDX\/celldex-reports-second-quarter-2025-financial-results-and-provides-l057wsu85430.html\">2025 2. \u00c7eyrek Sonu\u00e7lar\u0131<\/a>)<\/li> <li><strong>\u00d6nceki Model<\/strong>: Biyoteknoloji hisseleri genellikle klinik deneme sonu\u00e7lar\u0131 ve FDA g\u00fcncellemeleri etraf\u0131nda volatilite ya\u015far. Faz 2 eozinofilik \u00f6zofajit sonu\u00e7lar\u0131n\u0131n ard\u0131ndan %8,3'l\u00fck d\u00fc\u015f\u00fc\u015f bu hassasiyeti g\u00f6steriyor (<a href=\"https:\/\/simplywall.st\/stocks\/us\/pharmaceuticals-biotech\/nasdaq-cldx\/celldex-therapeutics\/news\/celldex-therapeutics-cldx-is-down-83-after-barzolvolimab-mis\">Son Klinik Sonu\u00e7lar<\/a>)<\/li> <\/ul> <p>\u00d6nemli \u00e7\u0131kar\u0131m? Kazan\u00e7 raporlar\u0131 hem risk hem de f\u0131rsat yarat\u0131r\u2014stratejik giri\u015f noktalar\u0131 i\u00e7in m\u00fckemmeldir.<\/p> <h3>6 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h3> <p>Celldex, \u015eubat 2025'ten bu yana yat\u0131r\u0131mc\u0131lar\u0131 olduk\u00e7a hareketli bir yolculu\u011fa \u00e7\u0131kard\u0131:<\/p> <table> <thead> <tr><th>Ay<\/th><th>Fiyat Aral\u0131\u011f\u0131<\/th><th>Performans<\/th><th>Ana Etken<\/th><\/tr> <\/thead> <tbody> <tr><td>Mart 2025<\/td><td>17,63 $ - 22,33 $<\/td><td>-%11,76<\/td><td>Piyasa belirsizli\u011fi<\/td><\/tr> <tr><td>Nisan 2025<\/td><td>14,40 $ - 21,58 $<\/td><td>+%14,77<\/td><td>14,40 $ seviyesinde destek buldu<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>17,85 $ - 21,23 $<\/td><td>-%5,04<\/td><td>Konsolidasyon d\u00f6nemi<\/td><\/tr> <tr><td>Haziran 2025<\/td><td>19,25 $ - 24,03 $<\/td><td>+%2,88<\/td><td>Erken toparlanma i\u015faretleri<\/td><\/tr> <tr><td>Temmuz 2025<\/td><td>20,01 $ - 24,05 $<\/td><td>+%13,34<\/td><td>G\u00fc\u00e7l\u00fc momentum olu\u015fumu<\/td><\/tr> <tr><td>A\u011fustos 2025<\/td><td>20,71 $ - 25,54 $<\/td><td>Devam ediyor<\/td><td>Klinik deneme g\u00fcncellemeleri<\/td><\/tr> <\/tbody> <\/table> <p>Bu volatilite rastgele de\u011fildir\u2014klinik a\u015famadaki biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n y\u00fcksek risk, y\u00fcksek getiri do\u011fas\u0131n\u0131 yans\u0131t\u0131r. Hisse, Nisan ay\u0131ndaki 14,40 $ dip seviyesinden yakla\u015f\u0131k %66 oran\u0131nda etkileyici bir toparlanma g\u00f6sterdi.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik ilerlemeye dayanarak, gelecekte neler olabilir:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 40-50 $ aral\u0131\u011f\u0131 (G\u00fc\u00e7l\u00fc klinik veriler %100+ kazan\u00e7 sa\u011flayabilir)<br> <strong>2026 Projeksiyonu<\/strong>: 55-70 $ (Olas\u0131 FDA ba\u015fvurular\u0131 ve ortakl\u0131klar)<br> <strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 80-120 $ (Onaylar ger\u00e7ekle\u015firse ticarile\u015fme a\u015famas\u0131)<br> <strong>2030 Vizyonu<\/strong>: 150-200+ $ (\u0130mm\u00fcnoloji alan\u0131nda yerle\u015fik piyasa konumu)<\/p> <p><strong>Karar<\/strong>: Risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Mevcut fiyat, potansiyel klinik kataliz\u00f6rler \u00f6ncesinde cazip bir giri\u015f sunuyor.<\/p> <h3>Bu Zamanlaman\u0131n \u00d6nemi<\/h3> <p>\u015eirketin 630,3 milyon $ nakit pozisyonu, 2027 y\u0131l\u0131na kadar finansal dayan\u0131kl\u0131l\u0131k sa\u011fl\u0131yor ve k\u0131sa vadeli seyrelme riskini azalt\u0131yor (<a href=\"https:\/\/www.stocktitan.net\/news\/CLDX\/celldex-reports-second-quarter-2025-financial-results-and-provides-l057wsu85430.html\">Finansal G\u00fc\u00e7<\/a>). Birden fazla Faz 3 denemesi devam etmekte olup, 2025-2026 y\u0131llar\u0131 d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc olabilir.<\/p> <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Biyoteknoloji Volatilitesinde Yol Alma<\/h2> <h3>Olas\u0131 Riskler<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Faz 3 denemelerinin %41'i ba\u015far\u0131s\u0131z olur\u2014herhangi bir aksakl\u0131k hisseyi \u00e7\u00f6kertebilir<\/li> <li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA reddi veya gecikmeleri gecede %50+ d\u00fc\u015f\u00fc\u015flere neden olabilir<\/li> <li><strong>Nakit T\u00fcketimi<\/strong>: \u00c7eyreklik 56,6 milyon $ zarar dikkatli sermaye y\u00f6netimi gerektirir<\/li> <li><strong>Rekabet<\/strong>: Benzer terapiler geli\u015ftiren b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li> <\/ul> <h3>2025 \u0130\u00e7in Olumlu Sinyaller<\/h3> <ul> <li><strong>Barzolvolimab Ba\u015far\u0131s\u0131<\/strong>: Kronik \u00fcrtiker denemelerinde %41 tam yan\u0131t oran\u0131 ola\u011fan\u00fcst\u00fc (<a href=\"https:\/\/www.stocktitan.net\/news\/CLDX\/celldex-reports-second-quarter-2025-financial-results-and-provides-l057wsu85430.html\">Deneme Sonu\u00e7lar\u0131<\/a>)<\/li> <li><strong>Pazar Potansiyeli<\/strong>: Kronik inflamatuar hastal\u0131klar d\u00fcnya \u00e7ap\u0131nda milyonlarca ki\u015fiyi etkiliyor<\/li> <li><strong>G\u00fc\u00e7l\u00fc Nakit Pozisyonu<\/strong>: Acil finansman endi\u015fesi yok<\/li> <li><strong>Analist Deste\u011fi<\/strong>: 8 analist \"G\u00fc\u00e7l\u00fc Al\" \u00f6neriyor, ortalama hedef fiyat 46,13 $<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayanlar \u0130\u00e7in Ak\u0131ll\u0131 Strateji<\/h2> <p><strong>Bug\u00fcn\u00fcn Eylem Plan\u0131:<\/strong><\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-5'ini y\u00fcksek riskli biyoteknolojiye ay\u0131r\u0131n<\/li> <li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: T\u00fcm\u00fcn\u00fc bir kerede de\u011fil, par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li> <li><strong>Zarar Durdur Seviyeleri Belirleyin<\/strong>: Felaket d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 koruma sa\u011flay\u0131n (giri\u015f fiyat\u0131n\u0131n %15-20 alt\u0131nda \u00f6nerilir)<\/li> <li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: Kas\u0131m kazan\u00e7lar\u0131 ve klinik g\u00fcncellemeleri izleyin<\/li> <\/ol> <p><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: \"CLDX ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014inan\u0131lmaz potansiyel ama beklenmedik patlamalara meyilli. G\u00fcvenlik g\u00f6zl\u00fc\u011f\u00fcn\u00fcz\u00fc takmay\u0131 unutmay\u0131n!\"<\/p> <h2>\u2705 Ad\u0131m Ad\u0131m: Celldex Therapeutics (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Platformunuzu Se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul \u00fccretlere sahip bir arac\u0131 kurum se\u00e7in<\/td><\/tr> <tr><td>2<\/td><td>Do\u011frulamay\u0131 Tamamlay\u0131n<\/td><td>Kimlik belgelerinizi sa\u011flay\u0131n\u2014bu genellikle birka\u00e7 dakika s\u00fcrer<\/td><\/tr> <tr><td>3<\/td><td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"CLDX\" Aray\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Limit Emri Verin<\/td><td>\u00d6deyece\u011finiz maksimum fiyat\u0131 belirtin (23-24 $ \u00f6nerilir)<\/td><\/tr> <tr><td>6<\/td><td>Emir Detaylar\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td><td>Komisyon \u00fccretleri ve emir t\u00fcr\u00fcn\u00fc kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Sat\u0131n Al\u0131m\u0131 Ger\u00e7ekle\u015ftirin<\/td><td>Al\u0131m emrinizi onaylay\u0131n<\/td><\/tr> <tr><td>8<\/td><td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td><td>\u00d6nemli fiyat seviyelerinde bildirim al\u0131n<\/td><\/tr> <tr><td>9<\/td><td>Pozisyonu Takip Edin<\/td><td>Performans\u0131 d\u00fczenli olarak izleyin<\/td><\/tr> <tr><td>10<\/td><td>\u00c7\u0131k\u0131\u015f Stratejisi Planlay\u0131n<\/td><td>K\u00e2r alma ve zarar durdur seviyelerini \u00f6nceden belirleyin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option'\u0131n Yeni Yat\u0131r\u0131mc\u0131lara \u00c7ekicili\u011fi<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, biyoteknoloji yat\u0131r\u0131mlar\u0131yla m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <p><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak, volatil CLDX gibi hisselerde stratejileri d\u00fc\u015f\u00fck riskle test edebilirsiniz.<\/p> <p><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: 1 dakikal\u0131k KYC s\u00fcreci, piyasa f\u0131rsatlar\u0131n\u0131 hemen de\u011ferlendirebilmenizi sa\u011flar.<\/p> <p><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: 100'den fazla y\u00f6ntemle, karlar\u0131n\u0131z\u0131 kripto, e-c\u00fczdan veya geleneksel bankac\u0131l\u0131k yoluyla kolayca \u00e7ekebilirsiniz.<\/p> <p>Bu eri\u015filebilirlik ve esneklik kombinasyonu, b\u00fcy\u00fck miktarlara ba\u011fl\u0131 kalmadan y\u00fcksek potansiyelli biyoteknoloji hisselerini ke\u015ffetmek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option'\u0131 \u00f6zellikle uygun k\u0131lar.<\/p> <h2>\ud83c\udf0d 2025'te Celldex Therapeutics: \u0130mm\u00fcnoloji Yenilik\u00e7isi<\/h2> <p>Celldex, onkoloji odakl\u0131 bir \u015firketten saf imm\u00fcnoloji uzman\u0131na d\u00f6n\u00fc\u015ft\u00fc. Mast h\u00fccre arac\u0131l\u0131 hastal\u0131klara stratejik pivotlar\u0131, d\u00fcnya \u00e7ap\u0131nda milyonlarca ki\u015fiyi etkileyen kronik inflamatuar durumlarla m\u00fccadelede odaklanm\u0131\u015f bir yakla\u015f\u0131m\u0131 temsil ediyor.<\/p> <p>\u015eirketin \u00f6nc\u00fc ilac\u0131 barzolvolimab, KIT resept\u00f6r\u00fcn\u00fc hedefliyor\u2014kronik \u00fcrtiker, prurigo nodularis ve eozinofilik \u00f6zofajit gibi durumlar\u0131n tedavisinde devrim yaratabilecek yenilik\u00e7i bir y\u00f6ntem. 87 ara\u015ft\u0131rma bilimcisi dahil olmak \u00fczere 186 \u00e7al\u0131\u015fan\u0131yla g\u00fc\u00e7l\u00fc dahili geli\u015ftirme kapasitesine sahipler (<a href=\"https:\/\/stockanalysis.com\/stocks\/cldx\/company\/\">\u015eirket Profili<\/a>).<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Celldex ara\u015ft\u0131rma ekibi, mast h\u00fccrelerinin\u2014bir zamanlar basit alerji yan\u0131tlay\u0131c\u0131lar\u0131 olarak d\u00fc\u015f\u00fcn\u00fclen\u2014asl\u0131nda 50'den fazla farkl\u0131 inflamatuar durumda merkezi bir rol oynad\u0131\u011f\u0131n\u0131 ke\u015ffetti; bu da y\u0131ll\u0131k 20 milyar $'\u0131 a\u015fabilecek devasa bir potansiyel pazar a\u00e7\u0131yor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Celldex Therapeutics (CLDX) hisseleri <strong>22,46 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, son alt\u0131 ay i\u00e7indeki dramatik seyri g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda ilgin\u00e7 bir giri\u015f noktas\u0131 sunuyor.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: Takviminize <strong>5 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin! Celldex, bu tarihte bir sonraki kazan\u00e7 raporunu yay\u0131nlayacak. Tarihsel veriler, bu t\u00fcr olaylar\u0131n \u00f6nemli fiyat hareketlerine yol a\u00e7abilece\u011fini g\u00f6steriyor.<\/p>\n<h3>Kazan\u00e7 Etkisi Analizi: Tarih Bizlere Ne \u00d6\u011fretiyor<\/h3>\n<p>Son kazan\u00e7 tepkilerine bakmak, yat\u0131r\u0131m zamanlamas\u0131 i\u00e7in de\u011ferli dersler sunar:<\/p>\n<ul>\n<li><strong>7 A\u011fustos 2025 2. \u00c7eyrek Kazan\u00e7lar\u0131<\/strong>: Gelir tahminlerin alt\u0131nda kal\u0131rken, hisse ba\u015f\u0131na kazan\u00e7 (EPS) beklentileri hafif\u00e7e a\u015ft\u0131. Hisse senedi, kar\u0131\u015f\u0131k sonu\u00e7lara ra\u011fmen dayan\u0131kl\u0131l\u0131k g\u00f6sterdi ve uzun vadeli \u00fcr\u00fcn hatt\u0131na olan yat\u0131r\u0131mc\u0131 g\u00fcvenini yans\u0131tt\u0131 (<a href=\"https:\/\/www.stocktitan.net\/news\/CLDX\/celldex-reports-second-quarter-2025-financial-results-and-provides-l057wsu85430.html\">2025 2. \u00c7eyrek Sonu\u00e7lar\u0131<\/a>)<\/li>\n<li><strong>\u00d6nceki Model<\/strong>: Biyoteknoloji hisseleri genellikle klinik deneme sonu\u00e7lar\u0131 ve FDA g\u00fcncellemeleri etraf\u0131nda volatilite ya\u015far. Faz 2 eozinofilik \u00f6zofajit sonu\u00e7lar\u0131n\u0131n ard\u0131ndan %8,3&#8217;l\u00fck d\u00fc\u015f\u00fc\u015f bu hassasiyeti g\u00f6steriyor (<a href=\"https:\/\/simplywall.st\/stocks\/us\/pharmaceuticals-biotech\/nasdaq-cldx\/celldex-therapeutics\/news\/celldex-therapeutics-cldx-is-down-83-after-barzolvolimab-mis\">Son Klinik Sonu\u00e7lar<\/a>)<\/li>\n<\/ul>\n<p>\u00d6nemli \u00e7\u0131kar\u0131m? Kazan\u00e7 raporlar\u0131 hem risk hem de f\u0131rsat yarat\u0131r\u2014stratejik giri\u015f noktalar\u0131 i\u00e7in m\u00fckemmeldir.<\/p>\n<h3>6 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h3>\n<p>Celldex, \u015eubat 2025&#8217;ten bu yana yat\u0131r\u0131mc\u0131lar\u0131 olduk\u00e7a hareketli bir yolculu\u011fa \u00e7\u0131kard\u0131:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>Fiyat Aral\u0131\u011f\u0131<\/th>\n<th>Performans<\/th>\n<th>Ana Etken<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mart 2025<\/td>\n<td>17,63 $ &#8211; 22,33 $<\/td>\n<td>-%11,76<\/td>\n<td>Piyasa belirsizli\u011fi<\/td>\n<\/tr>\n<tr>\n<td>Nisan 2025<\/td>\n<td>14,40 $ &#8211; 21,58 $<\/td>\n<td>+%14,77<\/td>\n<td>14,40 $ seviyesinde destek buldu<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>17,85 $ &#8211; 21,23 $<\/td>\n<td>-%5,04<\/td>\n<td>Konsolidasyon d\u00f6nemi<\/td>\n<\/tr>\n<tr>\n<td>Haziran 2025<\/td>\n<td>19,25 $ &#8211; 24,03 $<\/td>\n<td>+%2,88<\/td>\n<td>Erken toparlanma i\u015faretleri<\/td>\n<\/tr>\n<tr>\n<td>Temmuz 2025<\/td>\n<td>20,01 $ &#8211; 24,05 $<\/td>\n<td>+%13,34<\/td>\n<td>G\u00fc\u00e7l\u00fc momentum olu\u015fumu<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>20,71 $ &#8211; 25,54 $<\/td>\n<td>Devam ediyor<\/td>\n<td>Klinik deneme g\u00fcncellemeleri<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Bu volatilite rastgele de\u011fildir\u2014klinik a\u015famadaki biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n y\u00fcksek risk, y\u00fcksek getiri do\u011fas\u0131n\u0131 yans\u0131t\u0131r. Hisse, Nisan ay\u0131ndaki 14,40 $ dip seviyesinden yakla\u015f\u0131k %66 oran\u0131nda etkileyici bir toparlanma g\u00f6sterdi.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik ilerlemeye dayanarak, gelecekte neler olabilir:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 40-50 $ aral\u0131\u011f\u0131 (G\u00fc\u00e7l\u00fc klinik veriler %100+ kazan\u00e7 sa\u011flayabilir)<br \/> <strong>2026 Projeksiyonu<\/strong>: 55-70 $ (Olas\u0131 FDA ba\u015fvurular\u0131 ve ortakl\u0131klar)<br \/> <strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 80-120 $ (Onaylar ger\u00e7ekle\u015firse ticarile\u015fme a\u015famas\u0131)<br \/> <strong>2030 Vizyonu<\/strong>: 150-200+ $ (\u0130mm\u00fcnoloji alan\u0131nda yerle\u015fik piyasa konumu)<\/p>\n<p><strong>Karar<\/strong>: Risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Mevcut fiyat, potansiyel klinik kataliz\u00f6rler \u00f6ncesinde cazip bir giri\u015f sunuyor.<\/p>\n<h3>Bu Zamanlaman\u0131n \u00d6nemi<\/h3>\n<p>\u015eirketin 630,3 milyon $ nakit pozisyonu, 2027 y\u0131l\u0131na kadar finansal dayan\u0131kl\u0131l\u0131k sa\u011fl\u0131yor ve k\u0131sa vadeli seyrelme riskini azalt\u0131yor (<a href=\"https:\/\/www.stocktitan.net\/news\/CLDX\/celldex-reports-second-quarter-2025-financial-results-and-provides-l057wsu85430.html\">Finansal G\u00fc\u00e7<\/a>). Birden fazla Faz 3 denemesi devam etmekte olup, 2025-2026 y\u0131llar\u0131 d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc olabilir.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Biyoteknoloji Volatilitesinde Yol Alma<\/h2>\n<h3>Olas\u0131 Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Faz 3 denemelerinin %41&#8217;i ba\u015far\u0131s\u0131z olur\u2014herhangi bir aksakl\u0131k hisseyi \u00e7\u00f6kertebilir<\/li>\n<li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA reddi veya gecikmeleri gecede %50+ d\u00fc\u015f\u00fc\u015flere neden olabilir<\/li>\n<li><strong>Nakit T\u00fcketimi<\/strong>: \u00c7eyreklik 56,6 milyon $ zarar dikkatli sermaye y\u00f6netimi gerektirir<\/li>\n<li><strong>Rekabet<\/strong>: Benzer terapiler geli\u015ftiren b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Olumlu Sinyaller<\/h3>\n<ul>\n<li><strong>Barzolvolimab Ba\u015far\u0131s\u0131<\/strong>: Kronik \u00fcrtiker denemelerinde %41 tam yan\u0131t oran\u0131 ola\u011fan\u00fcst\u00fc (<a href=\"https:\/\/www.stocktitan.net\/news\/CLDX\/celldex-reports-second-quarter-2025-financial-results-and-provides-l057wsu85430.html\">Deneme Sonu\u00e7lar\u0131<\/a>)<\/li>\n<li><strong>Pazar Potansiyeli<\/strong>: Kronik inflamatuar hastal\u0131klar d\u00fcnya \u00e7ap\u0131nda milyonlarca ki\u015fiyi etkiliyor<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc Nakit Pozisyonu<\/strong>: Acil finansman endi\u015fesi yok<\/li>\n<li><strong>Analist Deste\u011fi<\/strong>: 8 analist &#8220;G\u00fc\u00e7l\u00fc Al&#8221; \u00f6neriyor, ortalama hedef fiyat 46,13 $<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayanlar \u0130\u00e7in Ak\u0131ll\u0131 Strateji<\/h2>\n<p><strong>Bug\u00fcn\u00fcn Eylem Plan\u0131:<\/strong><\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-5&#8217;ini y\u00fcksek riskli biyoteknolojiye ay\u0131r\u0131n<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: T\u00fcm\u00fcn\u00fc bir kerede de\u011fil, par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>\n<li><strong>Zarar Durdur Seviyeleri Belirleyin<\/strong>: Felaket d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 koruma sa\u011flay\u0131n (giri\u015f fiyat\u0131n\u0131n %15-20 alt\u0131nda \u00f6nerilir)<\/li>\n<li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: Kas\u0131m kazan\u00e7lar\u0131 ve klinik g\u00fcncellemeleri izleyin<\/li>\n<\/ol>\n<p><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: &#8220;CLDX ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014inan\u0131lmaz potansiyel ama beklenmedik patlamalara meyilli. G\u00fcvenlik g\u00f6zl\u00fc\u011f\u00fcn\u00fcz\u00fc takmay\u0131 unutmay\u0131n!&#8221;<\/p>\n<h2>\u2705 Ad\u0131m Ad\u0131m: Celldex Therapeutics (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Platformunuzu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretlere sahip bir arac\u0131 kurum se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Do\u011frulamay\u0131 Tamamlay\u0131n<\/td>\n<td>Kimlik belgelerinizi sa\u011flay\u0131n\u2014bu genellikle birka\u00e7 dakika s\u00fcrer<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;CLDX&#8221; Aray\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Limit Emri Verin<\/td>\n<td>\u00d6deyece\u011finiz maksimum fiyat\u0131 belirtin (23-24 $ \u00f6nerilir)<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Emir Detaylar\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td>\n<td>Komisyon \u00fccretleri ve emir t\u00fcr\u00fcn\u00fc kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Sat\u0131n Al\u0131m\u0131 Ger\u00e7ekle\u015ftirin<\/td>\n<td>Al\u0131m emrinizi onaylay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td>\n<td>\u00d6nemli fiyat seviyelerinde bildirim al\u0131n<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Pozisyonu Takip Edin<\/td>\n<td>Performans\u0131 d\u00fczenli olarak izleyin<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejisi Planlay\u0131n<\/td>\n<td>K\u00e2r alma ve zarar durdur seviyelerini \u00f6nceden belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option&#8217;\u0131n Yeni Yat\u0131r\u0131mc\u0131lara \u00c7ekicili\u011fi<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, biyoteknoloji yat\u0131r\u0131mlar\u0131yla m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<p><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak, volatil CLDX gibi hisselerde stratejileri d\u00fc\u015f\u00fck riskle test edebilirsiniz.<\/p>\n<p><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: 1 dakikal\u0131k KYC s\u00fcreci, piyasa f\u0131rsatlar\u0131n\u0131 hemen de\u011ferlendirebilmenizi sa\u011flar.<\/p>\n<p><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: 100&#8217;den fazla y\u00f6ntemle, karlar\u0131n\u0131z\u0131 kripto, e-c\u00fczdan veya geleneksel bankac\u0131l\u0131k yoluyla kolayca \u00e7ekebilirsiniz.<\/p>\n<p>Bu eri\u015filebilirlik ve esneklik kombinasyonu, b\u00fcy\u00fck miktarlara ba\u011fl\u0131 kalmadan y\u00fcksek potansiyelli biyoteknoloji hisselerini ke\u015ffetmek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option&#8217;\u0131 \u00f6zellikle uygun k\u0131lar.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Celldex Therapeutics: \u0130mm\u00fcnoloji Yenilik\u00e7isi<\/h2>\n<p>Celldex, onkoloji odakl\u0131 bir \u015firketten saf imm\u00fcnoloji uzman\u0131na d\u00f6n\u00fc\u015ft\u00fc. Mast h\u00fccre arac\u0131l\u0131 hastal\u0131klara stratejik pivotlar\u0131, d\u00fcnya \u00e7ap\u0131nda milyonlarca ki\u015fiyi etkileyen kronik inflamatuar durumlarla m\u00fccadelede odaklanm\u0131\u015f bir yakla\u015f\u0131m\u0131 temsil ediyor.<\/p>\n<p>\u015eirketin \u00f6nc\u00fc ilac\u0131 barzolvolimab, KIT resept\u00f6r\u00fcn\u00fc hedefliyor\u2014kronik \u00fcrtiker, prurigo nodularis ve eozinofilik \u00f6zofajit gibi durumlar\u0131n tedavisinde devrim yaratabilecek yenilik\u00e7i bir y\u00f6ntem. 87 ara\u015ft\u0131rma bilimcisi dahil olmak \u00fczere 186 \u00e7al\u0131\u015fan\u0131yla g\u00fc\u00e7l\u00fc dahili geli\u015ftirme kapasitesine sahipler (<a href=\"https:\/\/stockanalysis.com\/stocks\/cldx\/company\/\">\u015eirket Profili<\/a>).<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Celldex ara\u015ft\u0131rma ekibi, mast h\u00fccrelerinin\u2014bir zamanlar basit alerji yan\u0131tlay\u0131c\u0131lar\u0131 olarak d\u00fc\u015f\u00fcn\u00fclen\u2014asl\u0131nda 50&#8217;den fazla farkl\u0131 inflamatuar durumda merkezi bir rol oynad\u0131\u011f\u0131n\u0131 ke\u015ffetti; bu da y\u0131ll\u0131k 20 milyar $&#8217;\u0131 a\u015fabilecek devasa bir potansiyel pazar a\u00e7\u0131yor.<\/p>\n"},"faq":[{"question":"Celldex Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir arac\u0131 kurum se\u00e7in, kimlik do\u011frulamas\u0131n\u0131 tamamlay\u0131n, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"CLDX\" sembol\u00fc ile arama yap\u0131n, limit emri verin ve sat\u0131n alma i\u015flemini onaylay\u0131n."},{"question":"Celldex Therapeutics'in 2025 fiyat tahmini nedir?","answer":"2025 y\u0131l sonu i\u00e7in fiyat tahmini 40-50 $ aral\u0131\u011f\u0131nda olup, g\u00fc\u00e7l\u00fc klinik verilerle %100'\u00fcn \u00fczerinde kazan\u00e7 potansiyeli bulunmaktad\u0131r."},{"question":"Celldex Therapeutics yat\u0131r\u0131m\u0131nda riskler nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, reg\u00fclasyon engelleri, y\u00fcksek nakit t\u00fcketimi ve rekabet \u00f6nemli riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar i\u00e7in Celldex hisselerinde yat\u0131r\u0131m stratejisi nedir?","answer":"Portf\u00f6y\u00fcn %2-5'i ile k\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyeti ortalamas\u0131 yap\u0131n, zarar durdur seviyeleri belirleyin ve \u00f6nemli kataliz\u00f6rleri takip edin."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama ve \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ile y\u00fcksek potansiyelli biyoteknoloji hisselerine eri\u015fimi kolayla\u015ft\u0131r\u0131r."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Celldex Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir arac\u0131 kurum se\u00e7in, kimlik do\u011frulamas\u0131n\u0131 tamamlay\u0131n, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"CLDX\" sembol\u00fc ile arama yap\u0131n, limit emri verin ve sat\u0131n alma i\u015flemini onaylay\u0131n."},{"question":"Celldex Therapeutics'in 2025 fiyat tahmini nedir?","answer":"2025 y\u0131l sonu i\u00e7in fiyat tahmini 40-50 $ aral\u0131\u011f\u0131nda olup, g\u00fc\u00e7l\u00fc klinik verilerle %100'\u00fcn \u00fczerinde kazan\u00e7 potansiyeli bulunmaktad\u0131r."},{"question":"Celldex Therapeutics yat\u0131r\u0131m\u0131nda riskler nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, reg\u00fclasyon engelleri, y\u00fcksek nakit t\u00fcketimi ve rekabet \u00f6nemli riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar i\u00e7in Celldex hisselerinde yat\u0131r\u0131m stratejisi nedir?","answer":"Portf\u00f6y\u00fcn %2-5'i ile k\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyeti ortalamas\u0131 yap\u0131n, zarar durdur seviyeleri belirleyin ve \u00f6nemli kataliz\u00f6rleri takip edin."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama ve \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ile y\u00fcksek potansiyelli biyoteknoloji hisselerine eri\u015fimi kolayla\u015ft\u0131r\u0131r."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T20:20:55+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T20:20:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/\",\"name\":\"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"datePublished\":\"2025-08-25T20:20:55+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T20:20:55+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T20:20:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/","name":"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","datePublished":"2025-08-25T20:20:55+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celldex-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Celldex Therapeutics, Inc. (CLDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Celldex Therapeutics, Inc. (CLDX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":351025,"slug":"how-to-buy-celldex-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Celldex Therapeutics, Inc. (CLDX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Celldex Therapeutics, Inc. (CLDX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-celldex-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":351022,"slug":"how-to-buy-celldex-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Celldex Therapeutics, Inc. (CLDX) - Investimento em a\u00e7\u00f5es da Celldex Therapeutics, Inc. (CLDX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-celldex-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=351027"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351027\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334027"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=351027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=351027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=351027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}